- AdventHealth

Last fall, an AdventHealth physician and his team researched and developed a new brain-eating amoeba test which can produce results within three hours.
WHY IT MATTERS:
Previously, testing routinely took up to six days, while the amoeba kills its host in only 3-7 days, making identifying and treating the condition extremely urgent and difficult.
KEY UPDATE:
Over the past 10 months, Jose Alexander, M.D., clinical microbiologist and director of microbiology, virology and immunology for AdventHealth Orlando, and his team have run several experiments on their recently developed brain-eating amoeba test to further improve its results. The result is an extended viable testing window, which allows for simplified shipping and accelerates diagnosis, ultimately improving patient outcomes.
“We’ve run these Rapid Amoeba PCR tests through several sample transportation temperatures to determine sample stability and quality,” said Alexander. “Spinal fluid samples can now be shipped at room temperature if testing is expected within 48 hours and refrigerated if expected within seven days.”
Alexander believes the enhanced sample stability for rapid Amoeba PCR testing at different temperatures is a game changer because it enables faster, more effective treatment for patients by simplifying and expediting specimen packaging and shipment, still providing accurate and reliable results by direct testing on the sample upon arrival.
GO DEEPER:
The groundbreaking brain-eating amoeba test developed last fall has changed the landscape of how physicians treat this severe, and most of the time deadly, infection by cutting down the diagnosis time from days to hours. In fact, the brain-eating amoeba, also known as Naegleria fowleri, is one of several growing health concerns across the U.S. It kills more than 97% of people infected due to delays in identifying and treating the illness.
By going a step further and testing for stability and quality, Alexander and his team have developed a more efficient diagnostic tool for physicians allowing for a rapid turnaround time from collection to result, without delays due to sample freezing, special packaging and the ability to still provide reliable and clinically actionable results. This sample shipping is available for cases that are too far from Orlando, like Miami or out of state.
“AdventHealth is accepting samples for testing from any hospital across the U.S.,” said Alexander.
For physicians with medical staff privileges at AdventHealth, this new test is currently available in Epic as “Amoeba Screen, CSF.” For physicians at AdventHealth locations not yet on Epic, the test is available as a send out to AdventHealth Orlando as a reference laboratory. All other physicians can contact Jose Alexander, M.D. at jose.alexander@adventhealth.com for more information or for potential cases.
To read more about the recently developed test used to detect brain-eating amoebas, learn about these deadly infections and discover how the team repurposed a test used for other viruses to drive the innovation journey, click here.
Recent News
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...
Metabolic dysfunction associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at...
AdventHealth East Orlando recently became the first hospital in Florida to earn Advanced Foot & Ankle Surgery Certification from DNV, a worldwide, independent certification body.
With an aging population and increases in the prevalence of neurological conditions like Alzheimer’s disease and dementia, physicians and patients alike continue to seek new tools and approaches to...
In a new article published in the medical journal Age and Ageing, AdventHealth Research Institute’s Dr. Audrey Collins shares the results of a recent study evaluating the impact of exercise on...